Tải bản đầy đủ (.ppt) (42 trang)

Tuberculosis and HIV potx

Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (1.51 MB, 42 trang )

1
Tuberculosis and HIV
VCHAP
Vietnam-CDC-Harvard Medical School
AIDS Partnership
2
Learning Objectives







 
!"

#$
%



3
Outline of Talk

&

'
()*

(


+%()*!*,
/#

(
+%()*


4
TB/HIV co-infection: HIV prevalence
among TB patients in some provinces

0$
5
Incidence of Active TB in Persons with
Positive Tuberculin Skin Test
Am J Resp Crit Care Med 2000 Apr;161 (4 Pt 2 ): S221-47
Risk Factor TB Cases/1000
person-years
TB infection < 1 year ago 12.9
TB infection 1-7 years ago 1.6
HIV/AIDS 35 – 162
HIV + Injection Drug User 76
HIV – Injection Drug User 10
6
OI distribution in 100 HIV/AIDS patients at
Tropical Disease Hospital (HCMC) - 2000

Oral thrush

Tuberculosis


Wasting syndrome*

Respiratory infections

Cryptococcosis

Penicilliosis

PCP

Septicemia
53%
37%
34%
13%
9%
7%
5%
4%
Louie JK, Nguyen HC et al. Inter Jrnl of STD & AIDS 2004;15:758 - 761
*50% of pts with this diagnosis, grew + cultures for MTB
7
OI distribution in 220 HIV/AIDS inpatients at
NIITD (Hanoi) 2001-2002

Oral thrush 43 %

Wasting syndrome 33%


Tuberculosis 28%

Penicilliosis 11%

Shingles 5%

Septicemia 5%

Cerebral toxoplasmosis 3%

MAC infection 3%

PCP 2%

Leishmaniasis 0,5%

Aspergillosis 0,5%
Le Dang Ha et al.2001-2002
Clinical Presentation of the
PLWHA with Tuberculosis
9
The effect of HIV infection on signs
and symptoms of TB
Symptom/sign HIV positive (%)
HIV negative (%)
Dyspnea
Fever
Sweats
Weight loss
Diarrhea

Hepatomegaly
Splenomegaly
Lymphadenopathy
97
79
83
89
23
41
40
35
81
62
64
83
4
21
15
13
Chest 1994;106:1471-6
10
Clinical presentation and CD4

(
1'23
4 56

"

cough with or without bloody sputum


upper lobe disease, cavitations

pleural effusions

fever, weight loss etc
11
Clinical presentation and CD4

($
1'27
5$


fever, weight loss with minimal cough

AIDS wasting syndrome

extrapulmonary disease

atypical chest radiographs

smear negative tuberculosis
12
Sputum smear and HIV status
Tubercle Lung Dis 1993;75:191-4
13
Chest XRAY findings in patients with TB/HIV
Early stages of HIV (CD4 > 500)


infiltrates predominantly in upper lobes

pulmonary cavities present

pleural effusions
Advanced stages of HIV (CD4 < 200)

pulmonary cavities absent

infiltrates in middle and lower lobes

nodular infiltrates

effusions can be pleural and pericardial

mediastinal lymphadenopathy with no
pulmonary infiltrates

normal CXR
Diagnosing Tuberculosis in
the PLWHA
WHO 2006 Case Definitions for
Tuberculosis
15
New Perspectives on the Case Definition of
Tuberculosis

 /*,
6
8"


 /*,
$

$"
16
2006 WHO case definition
Smear positive pulmonary TB (SPPTB)



%$
9


,
%$
9():0

$(



,
$9():0
$
;""

,
%

$9

)
8



0
$
"
Non-HIV settings HIV prevalent settings-NEW
17
2006 WHO case definition
Smear negative pulmonary TB (SNPTB)

$

9

<

$

=








$
9

<
$

)8

,<

0$





 ,<

9
$
$
;
Non-HIV settings HIV prevalent settings-NEW
18
2006 WHO case definition
Extrapulmonary TB (EPTB)

,$


,<


$
$
%




"

,
%
$;
$9
,<


$
$
%

)8

,<

0$






HIV prevalent settings-NEWNon-HIV settings
Evaluation and Management of the
PLWHA suspected to have
Tuberculosis
20
New WHO Perspectives on the Evaluation and
Management of the PLWHA suspected to have TB

=$

"

$8

Adult HIV prevalence rate among pregnant women is ≥1% or HIV
prevalence among TB patients is ≥5%.


Setting : country, sub-national administration unit (e.g., district, county),
selected facility (e.g., referral hospital, drug rehabilitation centre)

9$
7>?
8$

21
22

23
Key WHO recommendations in 2006


1@5

9

$

'A<'
24
Key WHO recommendations in 2006

B%
%




HIV staging (clinical , immunological)

PCP treatment

Co-trimoxazole preventive therapy

'%

$


<0
=$$
25
Key 2006 WHO Recommendations for Smear negative
TB (SNPTB) and/or Extrapulmonary TB (EPTB):
“THE ANTIBIOTIC TRIAL”

C*
$

D
"E

C:
9D$
$"
C

Tài liệu bạn tìm kiếm đã sẵn sàng tải về

Tải bản đầy đủ ngay
×